Navigation Links
King's to develop unique sunscreen with Aethic

King's College London has entered into an agreement with skincare company Aethic to develop the first sunscreen based on MAA's (mycosporine-like amino acids), produced by coral.

It was last year that a team led by Dr Paul Long at King's discovered how the naturally-occurring MAA's were produced. Algae living within coral make a compound that is transported to the coral, which then modifies it into a sunscreen for the benefit of both the coral and the algae. Not only does this protect them both from UV damage, but fish that feed on the coral also benefit from this sunscreen protection.

The next phase of development is for the researchers to work with Professor Antony Young and colleagues at the St John's Institute of Dermatology at King's, to test the efficacy of the compounds using human skin models.

Aethic's Sve sunscreen was selected as the best 'host' product for the compound because of its existing broad-spectrum UVA/UVB and photo-stability characteristics and scientifically proven ecocompatibility credentials.

Dr Paul Long, Reader in Pharmacognosy at King's Institute of Pharmaceutical Science, said: "While MAA's have a number of other potential applications, human sunscreen is certainly a good place to begin proving the compound's features. If our further studies confirm the results we are expecting, we hope that we will be able to develop a sunscreen with the broadest spectrum of protection. Aethic has the best product and philosophy with which to proceed this exciting project."

Allard Marx, CEO of Aethic, added: "With the recent launch of Sve we believe that we are already leading the industry. Together with King's we would like to raise our product benefits to an even higher level using MAA's. We are very excited about the potential."

Contact: Emma Reynolds
King's College London

Page: 1

Related medicine news :

1. Tumor cells inner workings predict cancer progression
2. LWW announces 57% growth in 2011 impact factor rankings
3. Former Vikings and NFL Greats Tackle Sleep Apnea at Upcoming Minneapolis Event
4. Strategy developed to improve delivery of medicines to the brain
5. New collaboration to develop treatments for liver disease
6. Kids Develop Sense of Humor by Age 1, Study Finds
7. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
8. New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease
9. A model for development
10. NIH scientists map first steps in flu antibody development
11. Adelaide joins with Italy to develop super spaghetti
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: